برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Eprontia (topiramate) Oral Solution Date of Approval: November 5, 2021 Company: Azurity Pharmaceuticals, Inc. Treatment for: Epilepsy, Migraine Prevention Eprontia (topiramate) is a ready-to-use liquid formulation of the approved anticonvulsant topiramate for use in the treatment of epilepsy and the preventive treatment of migraine. https://t.me/ppdprogram

➡️Scemblix (asciminib) Tablets Date of Approval: October 29, 2021 Company: Novartis Treatment for: Chronic Myelogenous Leukemia Scemblix (asciminib) is a tyrosine kinase inhibitor used for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). https://t.me/ppdprogram

➡️Tyrvaya (varenicline) Nasal Spray Date of Approval: October 15, 2021 Company: Oyster Point Pharma, Inc. Treatment for: Dry Eye Disease Tyrvaya (varenicline) is a nasally administered selective cholinergic agonist for the treatment of the signs and symptoms of dry eye disease. https://t.me/ppdprogram

➡️Zimhi (naloxone hydrochloride) Injection Date of Approval: October 15, 2021 Company: Adamis Pharmaceuticals Corporation Treatment for: Opioid Overdose Zimhi (naloxone hydrochloride) is a high-dose formulation of the approved opioid antagonist naloxone for use in the treatment of opioid overdose. https://t.me/ppdprogram

➡️Tavneos (avacopan) Capsules Date of Approval: October 7, 2021 Company: ChemoCentryx, Inc. Treatment for: ANCA-Associated Vasculitis Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist for the adjunctive treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.me/ppdprogram

➡️Qulipta (atogepant) Tablets Date of Approval: September 28, 2021 Company: AbbVie Inc. Treatment for: Migraine Prevention Qulipta (atogepant) is an oral, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults. https://t.me/ppdprogram

➡️Opzelura (ruxolitinib) Cream Date of Approval: September 21, 2021 Company: Incyte Treatment for: Atopic Dermatitis Opzelura (ruxolitinib) cream is a topical Janus kinase (JAK) inhibitor used for the treatment of atopic dermatitis. https://t.me/ppdprogram

➡️Tivdak (tisotumab vedotin-tftv) Lyophilized Powder for Injection Date of Approval: September 20, 2021 Company: Seagen Inc. Treatment for: Cervical Cancer Tivdak (tisotumab vedotin-tftv) is a tissue factor-directed antibody and microtubule inhibitor conjugate for the treatment of patients with recurrent or metastatic cervical cancer. https://t.me/ppdprogram

➡️Trudhesa (dihydroergotamine mesylate) Nasal Spray Date of Approval: September 2, 2021 Company: Impel NeuroPharma, Inc. Treatment for: Migraine Trudhesa (dihydroergotamine mesylate) is a nasally administered dihydroergotamine (DHE) formulation for the acute treatment of migraine with or without aura in adults. https://t.me/ppdprogram

➡️Skytrofa (lonapegsomatropin-tcgd) for Injection Date of Approval: August 25, 2021 Company: Ascendis Pharma A/S Treatment for: Pediatric Growth Hormone Deficiency Skytrofa (lonapegsomatropin-tcgd) is a human growth hormone used once-weekly for the treatment of pediatric growth hormone deficiency. https://t.me/ppdprogram

➡️Korsuva (difelikefalin) Injection Date of Approval: August 23, 2021 Company: Cara Therapeutics, Inc. Treatment for: Chronic Kidney Disease-Associated Pruritus Korsuva (difelikefalin) is a selective peripheral kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). https://t.me/ppdprogram

➡️Twyneo (tretinoin and benzoyl peroxide) Cream Date of Approval: July 26, 2021 Company: Sol-Gel Technologies, Ltd. Treatment for: Acne Twyneo (tretinoin and benzoyl peroxide) is a topical retinoid and antibacterial fixed-dose combination for the treatment of acne vulgaris in adults and children 9 years of age and older. https://t.me/ppdprogram

➡️Bylvay (odevixibat) Capsules Date of Approval: July 20, 2021 Company: Albireo Pharma, Inc. Treatment for: Progressive Familial Intrahepatic Cholestasis (PFIC) Bylvay (odevixibat) is an ileal bile acid transport (IBAT) inhibitor for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). https://t.me/ppdprogram

➡️(fexinidazole) Tablets Date of Approval: July 16, 2021 Company: Drugs for Neglected Diseases Initiative Treatment for: Trypanosomiasis Fexinidazole is a nitroimidazole antibacterial indicated for the treatment of human African trypanosomiasis (African sleeping sickness) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. https://t.me/ppdprogram

➡️Kerendia (finerenone) Tablets Date of Approval: July 9, 2021 Company: Bayer Treatment for: Chronic Kidney Disease Associated with Type 2 Diabetes Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA) for the treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). https://t.me/ppdprogram

➡️Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Injection Date of Approval: June 30, 2021 Company: Jazz Pharmaceuticals plc Treatment for: Acute Lymphoblastic Leukemia Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). https://t.me/ppdprogram

➡️Verkazia (cyclosporine) Ophthalmic Emulsion Date of Approval: June 23, 2021 Company: Santen Inc. Treatment for: Vernal Keratoconjunctivitis Verkazia (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. https://t.me/ppdprogram

➡️Soaanz (torsemide) Tablets Date of Approval: June 14, 2021 Company: Sarfez Pharmaceuticals Treatment for: Edema Soaanz (torsemide) is a loop diuretic indicated for the treatment of edema associated with heart failure or renal disease in adults. https://t.me/ppdprogram

➡️Wegovy (semaglutide) Injection Date of Approval: June 4, 2021 Company: Novo Nordisk Treatment for: Obesity Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2). https://t.me/ppdprogram

➡️Astepro Allergy (azelastine) Nasal Spray Date of Approval: June 17, 2021 Company: Bayer HealthCare LLC Treatment for: Allergic Rhinitis Astepro Allergy (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis. https://t.me/ppdprogram